Abstracts tagged "Co-morbidities"

Abstract Number: 2442 • 2014 ACR/ARHP Annual Meeting
Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians
Anne F. Townsend^1,2,3,4, Paul Adam⁵, Jenny Leese⁶, Linda C. Li^6,7, Michael McDonald², Sheila Kerr⁸, Gordon Whitehead⁸ and Catherine Backman^6,9, ¹Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Maurice Young Centre for Applied Ethics, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Arthritis Patient Advisory Board, Richmond, BC, Canada, ⁹Department of Occupational Science & Occupational Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose Medical ethics evolves as health care develops. Digital health technologies are transforming health care delivery and patient and clinician relationships. Ethical approaches are shifting…
Abstract Number: 2113 • 2014 ACR/ARHP Annual Meeting
The Number of Morbidities Drives the Health Care Expenditures and Presence of a Musculoskeletal Condition Is Additionally Accountable for Higher Costs
Antje van der Zee-Neuen¹, Polina Putrik², Sofia Ramiro³, Andras Keszei⁴, Astrid M. Chorus⁵, Rob de Bie⁶ and Annelies Boonen⁷, ¹Internal Medicine, Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, RWTH Aachen University, Aachen, Germany, ⁵Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, ⁶Epidemiology, Maastricht University, Maastricht, Netherlands, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In Europe, 70- 80% of all healthcare expenses are attributable to chronic diseases and a large part of these are musculoskeletal conditions (MSKC).Having >1…
Abstract Number: 1833 • 2014 ACR/ARHP Annual Meeting
Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA)
Jessica Widdifield¹, Claire Bombardier², Jacqueline Young¹, Noah Ivers³, R. Liisa Jaakkimainen⁴, Sasha Bernatsky⁵, J. Michael Paterson¹, J. Carter Thorne⁶, Pooneh S.Akhavan⁷, Debra Butt¹, Vandana Ahluwalia⁸ and Karen Tu¹, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Little is known about the quality of care received by patients with multiple chronic conditions in primary care and whether quality care is different…
Abstract Number: 1844 • 2014 ACR/ARHP Annual Meeting
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…
Abstract Number: 2448 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis
Lianne S. Gensler¹, Michael M. Ward², MinJae Lee³, Mohammad Rahbar⁴, Matthew A. Brown⁵, John D. Reveille⁶ and Michael H. Weisman⁷, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ³Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁴The University of Texas Health Science Center at Houston, Houston, TX, ⁵Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA
Background/Purpose: Cardiovascular disease is an important comorbidity in inflammatory arthritis. There is evidence that AS patients have a significant burden of cardiovascular comorbidity. This appears…
Abstract Number: 1986 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study
Daria B. Crittenden¹, Binita Shah², Steven P. Sedlis², Christopher J. Swearingen³, Eric S. Wagner⁴, Yvette M. Henry⁴, Peter B. Berger⁴, Bruce N. Cronstein¹ and Michael H. Pillinger⁵, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Cardiology, New York, NY, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Geisinger Health System, Cardiovascular Center for Clinical Research, Danville, PA, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Gout patients have an increased risk of myocardial infarction (MI). Since atherosclerosis and plaque rupture are inflammatory processes, anti-inflammatory gout medications might also reduce…
Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Daria B. Crittenden¹, Jessica N. Kimmel¹, Virginia C. Pike¹, Daniel Diaz¹, Avni Shah², Cilian J. White¹, Michael DeBerardine², Grace Kim², Binita Shah³, Christopher J. Swearingen⁴, Jeffrey D. Greenberg⁵, Steven P. Sedlis³, Craig T. Tenner⁶, Bruce N. Cronstein¹ and Michael H. Pillinger², ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…
Abstract Number: 963 • 2013 ACR/ARHP Annual Meeting
Impact Of a Nurse-Led Program On Comorbidity Management In Rheumatoid Arthritis (RA): Results Of a Prospective, Multicenter, Randomized, Controlled Trial
Martin Soubrier¹, Elodie Perrodeau², Melanie Gilson³, Alain G. Cantagrel⁴, Xavier le Loet⁵, René-Marc Flipo⁶, Sandrine Guis⁷, Gael Mouterde⁸, Liana E. Euller-Ziegler⁹, Thierry Schaeverbeke¹⁰, Bruno Fautrel¹¹, Alain Saraux¹², Isabelle Chary-Valckenaere¹³, Gérard Chales¹⁴, Emmanuelle Dernis¹⁵, Pascal Richette¹⁶, Xavier Mariette¹⁷, Francis Berenbaum¹⁸, Jean Sibilia¹⁹, Philippe Ravaud²⁰ and Maxime Dougados²¹, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²Epidemiologist, Paris, France, ³CH Grenoble Hopital Sud, Grenoble, France, ⁴Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, ⁵Rheumatology Department, CHU de ROUEN, Rouen, France, ⁶Hôpitaux Universitaires de Lille, France, France, ⁷Rheumatology1, CRMBM UMR CNRS 7339, Aix Marseille Univ; AP-HM, Marseille, France, ⁸Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ⁹Service de Rhumatologie, L Archet Hospital (University), Nice CEDEX 3, France, ¹⁰Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹¹Rheumatology, UPMC - Paris 6 University, Paris, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Rheumatology, Nancy Teaching Hospital, Nancy, France, ¹⁴CHU RENNES, Rennes, France, ¹⁵Centre Hospitalier, Le Mans, France, ¹⁶Centre Viggo Petersen / Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁷Paris-Sud University, Paris, France, ¹⁸Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ¹⁹Rheumatology, CHU Hautepierre, Strasbourg, France, ²⁰Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of developing numerous comorbid conditions that affect both mortality and RA outcome. Objectives: To…
Abstract Number: 782 • 2013 ACR/ARHP Annual Meeting
Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Johan Askling¹, Niklas Berglind², Stefan Franzén², Thomas Frisell³, Christopher Garwood⁴, Jeffrey D. Greenberg⁵, Meilien Ho⁶, Marie Holmqvist¹, Laura Horne⁷, Kathy Lampl⁸, Kaleb Michaud⁹, Fredrik Nyberg¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁴, Hisashi Yamanaka¹⁵ and Deborah Symmons⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²AstraZeneca R&D Mölndal, Mölndal, Sweden, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁷AstraZeneca, Wilmington, DE, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰AstraZeneca R&D, Mölndal, Sweden, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer…
Abstract Number: 408 • 2013 ACR/ARHP Annual Meeting
Comorbidity In Early Rheumatoid Arthritis.Does Inflammation Matter ?
Lena Innala¹, Clara Sjöberg², Ewa H. Berglin³, Anna Södergren³, Bozena Möller⁴, Solbritt M. Rantapaa-Dahlqvist⁵ and Solveig Wållberg-Jonsson³, ¹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ²Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Department of Rheumatology, Sunderby Hospital, Luleå, Sweden, ⁵Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer from comorbidities that contribute to a shortened lifespan. The degree of inflammation is of importance for the development…
Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Anja Strangfeld¹, Yvette Meißner², Adrian Richter³, Matthias Schneider⁴, Hans Peter Tony⁵, Kerstin Gerhold⁶, Angela Zink⁷ and Joachim Listing³, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, University of Duesseldorf, Duesseldorf, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁶Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…
Abstract Number: 88 • 2013 ACR/ARHP Annual Meeting
Musculoskeletal Diseases Have The Worst Impact On Physical Health Compared With Other Diseases – Results Of The Dutch cross-Sectional Study
Antje van der Zee-Neuen¹, Polina Putrik², Sofia Ramiro³, Andras P. Keszei⁴, Rob de Bie⁵, Astrid M. Chorus⁶ and Annelies Boonen⁷, ¹Internal Medicine, Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Epidemiology, School for Oncology and Developmental Biology, Maastricht, Netherlands, ⁵Epidemiology, Maastricht University, Maastricht, Netherlands, ⁶Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Musculoskeletal conditions (MSKC) are among the most common chronic conditions. Increasingly, patients suffer from more than one disease. Moreover, the presence of a co-morbid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].